Table 2.
Serum IL-6 levels during COVID-19 in clinical trials considering tocilizumab and sarilumab
| Article | Serum concentration of interleukin-6 (ng/ml) | |||
|---|---|---|---|---|
| First author or study group | year | Réf. | Placebo / standard of care | Active |
| Tocilizumab | ||||
| Veiga VC | 2021 | [96] | 208 (586) | 192 (313) |
| RECOVERY | 2021 | [127] | - | - |
| Stone JH | 2020 | [43] | 25.4 (14.6–40.3) | 23.6 (14.0–49.9) |
| Salvarani C | 2020 | [42] | 34.3 (19.0–59.3) | 50.4 (28.3–93.2) |
| Lescure FX | 2021 | [52] | 13.0 (3.6–23.5) |
Two groups : 11.6 (5.1–23.5) 12.7 (5.5–26.5) |
| Soin AS | 2021 | [53] | 85.2 (232.2) | 115.5 (245.6) |
| Guaraldi G | 2020 | [56] | 144.1 (41.1–385.8) |
SC : 90.2 (86.6–401.0) IV : 238.3 -140.2–731.9) |
| Vazquez Guillamet MC | 2021 | [57] | 48 (26–512.5) | 66.8 (55–739.7) |
| Sarilumab | ||||
| SARICORa | 2021 | [120] | 8 (38-80) |
S200 mg: 59 (43-88) S400 mg: 70 (43-127) |
| SARTRE | 2021 | [58] | 13.25 [3.85–43.35] | 19.20 [6.00–46.00] |
| Sivapalasingam S | 2022 | [61] |
“severe patients” (median; min- max) 61.5 (9.10–571.26) “critical patients” 85.6 (9.1-2324.8) |
“severe patients” S200: 53.3 (9.1–1713.2) S400: 58.2 (9.10–2771.4) “critical patients” S200: 116.1 (6.82–6531.58) S400: 125.9 (9.1–21545.3) |
aPatients selected to have IL-6 ≥ 40 ng/ml or elevated
S200 Sarilumab: 200 mg, S400: Sarilumab: 400 mg, IV intravenous administration, SC subcutaneous administration